Citation: | LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302 |
[1] |
Zhao S,Xu W,Jiang W,et al.Regulation of cellular metabolism by protein lysine acetylation[J].Science,2010,327(5968):1000-1004.
|
[2] |
Tony K, Montellier E, Flint SJ, et al. Acetylation: a regulatory modification to rival phosphorylation[J]? EMBO J,2000,19(6):1176-1179.
|
[3] |
Filippakopoulos P,Picaud S,Mangos M,et al.Histone recognition and large-scale structural analysis of the human bromodomain family[J].Cell,2012,149(1):214-231.
|
[4] |
Shein NA,Shohami E.Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries[J].Mol Med,2011,13(3):29-39.
|
[5] |
Gaucher J, Boussouar F, Montellier E, et al. Bromodomain-dependent stage-specific male genome programming by Brdt[J].EMBO J,2012,31(19):3809-3820.
|
[6] |
LeRoy G,Rickards B,Flint SJ.The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription[J].Mol Cell,2008,30(1):51-60.
|
[7] |
Denis GV,McComb ME,Faller DV,et al.Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines[J].J Proteome Res,2006,5(10):502-511.
|
[8] |
Devaiah BN,Lewis BA,Cherman N,et al.BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain[J].Proc Natl Acad Sci U S A,2012,109(18):6927-6932.
|
[9] |
Denis GV,Green MR.A novel,mitogen-activated nuclear kinase is related to a Drosophila developmental regulator[J].Genes Dev,1996, 10(3):261-271.
|
[10] |
French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene:a novel mechanism in aggressive carcinoma[J].Cancer Res,2003, 63(2):304-307.
|
[11] |
Delmore JE, Knapp S, Kouzarides T, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc[J].Cell,2011, 146(6):904-917.
|
[12] |
Filippakopoulos P,Knapp S.The bromodomain interaction module[J].FEBS Lett,2012,586(17):2692-2704.
|
[13] |
Haynes SR,Dollard C,Winston F,et al.The bromodomain:a conserved sequence found in human,Drosophila and yeast proteins [J].Nucleic Acids Res,1992,20(10):2603.
|
[14] |
Rosner M,Hengstschlager M.Targeting epigenetic readers in cancer[J].N Engl J Med,2012,367(18):1764-1765.
|
[15] |
Filippakopoulos P,Knapp S.The bromodomain interaction module[J].FEBS Lett,2012,586(17):2692-2704.
|
[16] |
Winston F,Allis CD.The bromodomain:a chromatin-targeting module[J].Nat Struct Biol,1999,6(7):601-604.
|
[17] |
Dawson MA,Kouzarides T,Huntly BJP.Targeting epigenetic readers in cancer[J].N Eng J Med,2012,367(7):647-657.
|
[18] |
Mitsubishi Tanabe Pharma Corporation.Antitumor agent:WO,2009084693[P].2009-07-09[2015-01-14] .
|
[19] |
Terri H,Finkel J,Wang GB.Compositions and methods for the treatment of HIV:US,20140199260[P].2014-07-17[2015-01-14] .
|
[20] |
Dana-Farber Cancer Institute,Inc.Compositions and methods for treating neoplasia,inflammatory disease and other disorders:WO,2011143669[P].2011-11-17[2015-01-14] .
|
[21] |
David S,Timothy PC,Laura E,et al.Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions[J].J Med Chem,2011,55(19):9393-9413.
|
[22] |
Filippakopoulos P,Picaud S,Fedorov O,et al.Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family[J].Bioorg Med Chem,2012,20(6):1878-1886.
|
[23] |
Yoshitomi Pharmaceutical Industries. Thienotriazolodiazepine compounds and medicinal uses thereof:WO,1998011111[P].1998-02-19[2015-01-14] .
|
[24] |
Zhao Y,Yang CY,Wang S,et al.The making of I-BET762,a BET bromodomain inhibitor now in clinical development[J].J Med Chem,2013,56(19):7498-7500.
|
[25] |
Rguet O,Gosmini R,Toum J,et al.Discovery of epigenetic regulator I-BET762:lead optimization to afford a clinical candidate inhibitor of the BET bromodomains[J].J Med Chem, 2013,56(19):7501-7515.
|
[26] |
Bayer GMBH.BET-protein-inhibitors-5-aryl-triazolo-azepine:WO,2014048945[P].2014-04-03[2015-01-14] .
|
[27] |
Constellation Pharmaceuticals,Inc.Bromodomain inhibitors and uses thereof:WO,2012151512[P].2012-11-08[2015-01-14] .
|
[28] |
Constellation Pharmaceuticals,Inc.Bromodomain inhibitors and uses thereof:WO,2012174487[P].2012-12-10[2015-01-14] .
|
[29] |
Boehringer Ingelheim GMBH.Triazolopyridazine:US,20140135336 [P].2014-10-07[2014-05-15] .
|
[30] |
Fedorov O,Lingard H,Wells C,et al.[1,2,4] Triazolo[4,3-a ] phthalazines:inhibitors of diverse bromodomains[J].J Med Chem,2014,57(2):462-476.
|
[31] |
Hewings DS,Wang M,Philpott M,et al.3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands[J].J Med Chem,2011,54(19):6761-6770.
|
[32] |
Hewings DS,Fedorov O,Filippakopoulos P,et al.Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands[J].J Med Chem,2013,56(8):3217-3227.
|
[33] |
Bamborough P,Diallo H,Goodacre JD,et al.Fragment-based discovery of bromodomain inhibitors part 2:optimization of phenylisoxazole sulfonamides[J].J Med Chem,2012,55(2):587-596.
|
[34] |
Mirguet O,Lamotte Y,Donche F,et al.From ApoA1 upregulation to BET family bromodomain inhibition:discovery of I-BET151[J].Bioorg Med Chem Lett,2012,22(8):2963-2967.
|
[35] |
Seal J,Lamotte Y,Donche F,et al.Identification of a novel series of BET family bromodomain inhibitors:binding mode and profile of I-BET151(GSK1210151A)[J].Bioorg Med Chem Lett,2012,22(8):2968-2972.
|
[36] |
Glaxosmithkline LLC.Imidazo[4,5-C]quinoline derivates as bromodomain inhibitors:WO,2011054846[P].2011-05-12[2015-01-14] .
|
[37] |
Duncan H,Oleg F,Panagis F,et al.The design and synthesis of 5-and 6-isoxazolyl benzimidazoles as selective inhibitors of the BET bromodomains[J].Med Chem Comm,2013,4(8):140-144.
|
[38] |
Fedorov O,Martin S,Singleton DC,et al.Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains[J].J Am Chem Soc, 2013,10(37):1021-1034.
|
[39] |
Constellation Pharmaceuticals,Inc.Bromodomain inhibitors and uses thereof:WO,2012075383[P].2012-06-07[2015-01-14] .
|
[40] |
Victor SW,Michael CH,Rishi GV,et al.Discovery,design,and optimization of isoxazole azepine BET inhibitors[J].Med Chem Lett,2013,4(9):835-840.
|
[41] |
Hewings DS,Wang M,Philpott M,et al.3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands[J].J Med Chem,2011,54(10),6761-6770.
|
[42] |
Paul VF,Panagis F,Gerwyn B,et al.Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit[J].J Med Chem, 2012,55(22):9831-9837.
|
[43] |
Picaud S,Da C,Thanasopoulou A,et al.PFI-1,a highly selective protein interaction inhibitor,targeting BET bromodomains[J].Cancer Res,2013,73(11):3336-3346.
|
[44] |
Chung CW,Anthony WD,James M,et al.Fragment-based discovery of bromodomain inhibitors part 1:inhibitor binding modes and implications for lead discovery[J].J Med Chem,2012,55(2):576-586.
|
[45] |
Glaxosmithkline LLC.Tetrahydroquinolines derivatives as bromodomain inhibitors:WO,2011054848[P].2011-05-12[2015-01-14] .
|
[46] |
McLure KG,Gesner EM,Tsujikawa L,et al.RVX-208,an inducer of ApoA-I in humans,is a BET bromodomain antagonist[J].PLoS One,2013,8(12):3190-3201.
|
[47] |
Resverlogix Corp.Compounds for the prevention and treatment of cardiovascular diseases:WO,2008092231[P].2008-08-07[2015-01-14] .
|
[48] |
Nicholls SJ,Gordon A,Johansson J,et al.Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease:a randomized controlled trial[J].J Am Coll Cardiol,2011,57(23):1111-1119.
|
[49] |
Bayer GMBH.BET-protein inhibitors dihydropyridopyrazinone:WO,2014095774[P].2014-06-26[2015-01-14] .
|
[50] |
Zhao LL,Cao DY,Chen TT,et al.Fragment-based drug discovery of 2 thiazolidinones as inhibitors of the histone reader BRD4 bromodomain[J].J Med Chem, 2013,56(10):3833-3851
|
[51] |
Abbvie,Inc.Bromodomain inhibitors:WO,2013097601[P].2013-07-04[2015-01-14] .
|
[52] |
Lucas X,Wohlwend D,Hagle M,et al.4-Acyl pyrroles:mimicking acetylated lysines in histone code reading[J].Angew Chem Int Ed Engl,2013,52(52):14055-14059.
|